Figure 2From: A case of HER-2-positive recurrent breast cancer showing a clinically complete response to trastuzumab-containing chemotherapy after primary treatment of triple-negative breast cancerFluorescence in situ hybridization analysis of the primary tumor showed a lack of HER-2 amplification, with a ratio of 1.1.Back to article page